22 / 24
22
Receptor
Patients Treated
Cells Infused
ORR
ERBB2 (Her2/neu)
1
1e10
0/1
VEGFR2
23
1e6 – 3e10
1/23 (4%)
PR (2 months)
EGFRvIII
16
1e7 – 3e10
0/16
Mesothelin
14
1e6 – 1e8
0/13
(Pt. 14, too early)
Data from public NCI experience. Updated information published in Clin Cancer Research last week (Feb 1st 2018) and not included here
Inmunoterapia y biomarcadores: CART